Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
BIOJECT MEDICAL TECHNOLOGIES INC (BJCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/15/2010 |
8-K
| Form 8-K - Current report |
| 12/21/2009 |
8-K
| Appointed a new director|
Docs:
|
"Articles of Amendment to 2002 Restated Articles of Incorporation",
"Series G Convertible Preferred Stock Purchase Agreement between Bioject Medical Technologies Inc. Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P., and Edward Flynn",
"Registration Rights Agreement between Bioject Medical Technologies, Inc., Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P., Edward Flynn, Ralph Makar, David Tierney, Richard Stout, Christine Farrell, and the Investors listed on Exhibit A thereto",
"BIOJECT CLOSES PREVIOUSLY ANNOUNCED EQUITY FINANCING Completion of Series G Preferred Financing Converts Portion of Debt and Provides Cash PORTLAND, OR, December 21, 2009 - Bioject Medical Technologies Inc. , a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund II, L.P. , and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share. Gross proceeds from the sale were $1,201,834, payable by payment of $500,000 in cash and the cancellation of the $600,000 outstanding principal amount of and $101,834 accrued interest through D..." |
|
|
|